Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report. (PubMed, Cureus) - Sep 14, 2026 - "We present the case of a 51-year-old male with long-standing poorly controlled type 2 diabetes mellitus who developed euDKA shortly after initiation of empagliflozin/metformin therapy...The patient required intensive care management with intravenous fluids, insulin infusion, electrolyte monitoring, and dextrose-containing fluids, with subsequent complete resolution of metabolic abnormalities. This case adds to the growing body of literature describing euDKA in patients receiving SGLT2 inhibitor therapy in the setting of reduced oral intake and poorly controlled diabetes mellitus."
Journal • Critical care • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
|
|
Astrid J Batista; Jose C Serrano Reyes; Maria F Carrillo; Rolando L Jaen
|